Assessing the In Vitro Activity of Ceftazidime/Avibactam and Aztreonam Among Carbapenemase-Producing Enterobacteriaceae: Defining the Zone of Hope

In light of our recent report of clinical success with combination ceftazidime/avibactam plus aztreonam (CZA+ATM) therapy against a serine- and metallo- β-lactamase (MBL)-producing pathogen [1], we read with interest the letters by Davido et al. [2] and Shaw et al. [3] describing two additional clinical successes at a hospital in France and 6 similar successes recorded in Spain, respectively. Carbapenemase-producing Enterobacteriaceae (CPE) are amo ng the most threatening pathogens with the ability to simultaneously produce MBLs and serine-β-lactamases and a plethora of other resistance genes.

Source: International Journal of Antimicrobial Agents - July 22, 2018 Category: Drugs & Pharmacology Authors: Lindsay M. Avery, David P. Nicolau Tags: Short Communication Source Type: research